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Abstract
Endothelial nitric oxide synthase (eNOS) plays a critical role in regulating and maintaining a healthy cardiovascular system. The importance
of eNOS can be emphasized from the genetic polymorphisms of the eNOS gene, uncoupling of eNOS dimerization, and its numerous signaling regulations. The activity of eNOS on the cardiac myocytes, vasculature, and the central nervous system are discussed. The effects of eNOS on the sympathetic autonomic nervous system (SANS) and the parasympathetic autonomic nervous system (PANS), both of which profoundly influence the
cardiovascular system, will be elaborated. The relationship between the eNOS protein with cardiovascular autonomic reflexes such as the baroreflex
and the Exercise Pressor Reflex will be discussed. For example, the effects of endogenous nitric oxide (NO) are shown to be mediated by the eNOS
protein and that eNOS-derived endothelial NO is most effective in regulating blood pressure oscillations via modulating the baroreflex mechanisms.
The protective action of eNOS on the CVS is emphasized here because dysfunction of the eNOS enzyme is intricately correlated with the pathogenesis
of several cardiovascular diseases such as hypertension, arteriosclerosis, myocardial infarction, and stroke. Overall, our current understanding of
the eNOS protein with a focus on its role in the modulation, regulation, and control of the cardiovascular system in a normal physiological state and
in cardiovascular diseases are discussed.
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Introduction
Previous reviews have summarized how a reduced expression of
the endothelial nitric oxide synthase (eNOS) enzyme and subsequent
decreased production of NO result in an increased susceptibility/
risk to develop essential hypertension [1,2], preeclampsia [3],
diabetic nephropathy [4], retinopathy [5], migraine [6], and
erectile dysfunction [7]; the role of the eNOS enzyme, including its
modulation, regulation, and relevance within the cardiovascular
system (CVS) in both normal physiological state and in several

important cardiovascular diseases is elaborated. In addition,
because the amount of NO generated by the vascular endothelial
cells plays critical roles in the regulation and maintenance of the
vascular tone, migration, production, proliferation, and maturation
of cells, leukocyte adhesion, and platelet aggregation, it can be
implied that eNOS is indeed an essential molecule for a properly
functioning and healthy CVS, thus emphasizing the protective
action of eNOS on the CVS.
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Endothelial Nitric Oxide Synthase
Endothelial NOS or eNOS is encoded by the NOS3 gene that is
in the 7q35-7q36 region of chromosome 7 in human beings (Figure
1). The eNOS enzyme protects the CVS, and this is because of its
ability to produce one of the most important neurotransmitters/
neuromodulators in a proportionate amount that is physiologically
beneficial to the CVS.
NO is widely known as an autocrine and paracrine signaling
factor that exerts numerous pleiotropic functions, such as
modulation of blood flow and circulation, thrombosis, inflammation,
immune regulation, as well as neural activity. In addition, a
review has summarized the important functions of NO that is
produced by eNOS which are its anti-thrombotic and anti-embolic
effects, particularly because of NO diffusion across the platelets’
membranes, activating sGC, and ultimately resulting in attenuating
platelet aggregation or platelet clumping [8]. Further research in the
future will most definitely provide additional important functions
of the eNOS protein in the protection of not only the CVS, but also
in neuroprotection (see below) of the nervous system as well as
other systems, including immunological responses in humans. For
example, a review discusses the amount of NO that is generated by
eNOS having excellent protective antioxidant properties because of
its ability to decrease the formation of superoxide anion, commonly
referred to as “free radicals”, mediated via NO-induced increases

in the expression of superoxide dismutase, an antioxidant enzyme
that catalyzes the conversion of superoxide anion into hydrogen
peroxide (H2O2) [9]. The antioxidant properties of NO produced
by eNOS are also due to the up-regulation of heme-oxygenase-I
and ferritin expression, that in turn, attenuate superoxide anion
concentrations within the vasculature in general [10]. For
example, superoxide anion radical (O2∙) is generated via numerous
enzymatic processes, autooxidation reactions, and nonenzymatic
electron transfer reactions and produces the most important
widespread reactive oxygen species (ROS) [11,12]. In addition, a
reaction between O2∙ and NO produces a toxic molecule known as
peroxynitrite (OONO-) that interacts with carbon dioxide (CO2) and
changes into highly reactive nitroso peroxocarboxylate (ONOOCO2-)
or peroxynitrous acid (ONOOH). This reaction can oxidize lipids,
oxidize methionine and tyrosine residues in proteins, and it can
further oxidize DNA to form nitroguanine [13]. Finally, NO can react
with other radicals such as H2O2 and HOCl that are converted into
N2O3, NO2- and NO3- [14].

Polymorphisms in eNOS Gene

The eNOS gene is located on chromosome 7q35-36 with welldefined polymorphisms (Figure 1) [15]. This location of eNOS on
chromosome 7 has been shown to be highly correlated to several
life-threatening cardiovascular disease processes, including
ruptures of aneurysms and congenital cardiac anomalies [15].

Figure 1: Scheme of the gene encoding endothelial nitric oxide synthase (eNOS). The human eNOS gene is located at 7q35-36 and it contains
26 exons with the start transcription site designated by AUG in the promoter region; polymorphisms are indicated in the promotor region and
exon 7. Scheme of the eNOS protein is also shown on the extreme right.
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The polymorphisms in the eNOS gene are closely associated
with a higher incidence of cardiovascular diseases (CVD). For
example, the C allele for the NOS3-786T > C polymorphism of the
eNOS gene causes decreased eNOS expression and subsequently an
attenuated production of NO [16]. Patients with such a condition
will have an increased risk of developing hypertension [17],
preeclampsia [18], diabetic nephropathy [19], retinopathy [19],
and migraine [20]. The 786T > C is also associated with higher
episodes of coronary vasospasm [21]. In patients with a four-repeat
allele of the variable number tandem repeats in this genetic variant,
there has been an increased risk of aneurysm ruptures, while the
C-allele of the 786T > C single-nucleotide polymorphism variant is
significantly associated with the occurrence of aneurysm rupture
followed by subarachnoid hemorrhage and vasospasm [22-24].
Another variation known as 894G > T is linked to coronary
and carotid artery diseases such as myocardial infarction (MI)
and carotid arteriosclerosis [25-27]. The 894T > G eNOS single
nucleotide polymorphism has been suggested to be responsible
for not only a reduced synthesis of NO but also in the development
of essential hypertension, particularly in Caucasians and in North
African populations [28]. In addition, a previous publication
has shown for the first time a highly significant association of
ambulatory blood pressure with eNOS haplotypes in a significant
white population living in northern Belgium, further suggesting
a direct relationship of eNOS polymorphisms on blood pressure
[29]. It appears that the above polymorphisms in the eNOS gene
have serious pathological impact on the function of the eNOS gene
and are involved with several CVD [30]. Overall, there have been
overwhelming cases that the eNOS gene is associated in patients
with not only CVD but also subjects with diabetes and congenital
heart defects.

eNOS Dimerization and Uncoupling

Serious clinical and pathological consequences related to
not only CVD like atherosclerosis and hypertension but also
situations such as diabetes mellitus and nicotine tolerance can
occur if the eNOS enzyme dimer gets uncoupled. To understand
the consequences of eNOS uncoupling, the structure and function
of eNOS as a dimer are briefly discussed. Endothelial NOS is a dimer
consisting of two identical monomers that have molecular weights
of 134 kD [31]. One of the monomers has a reductase domain that
consists of binding sites for nicotinamide adenine dinucleotide
phosphate (NADPH), flavin adenine dinucleotide (FAD), and flavin
mononucleotide (FMN). The other monomer is an oxygenase
domain and consists of heme, zinc, the cofactor tetrahydrobiopterin
(BH4), and L-arginine binding sites. A calmodulin-binding

sequence links the reductase domain with the oxygenase domain
(Figure 2). It is now known how NO is synthesized by eNOS from
L-arginine and molecular oxygen in the vascular endothelium.

Briefly, located at the reductase domain of eNOS, the FMN and FAD
molecules shuttle electrons from NADPH to the heme center in the
oxygenase domain for this NO production. Heme is reduced by the
reductase domain initially, which then binds with O2 and forms
an oxyferrous complex and reduction of this oxyferrous complex
uses electrons derived from NADPH located within the reductase
domain. However, interdomain electron transfer from NADPH
of the reductase domain to the oxygenase domain appears to be
slow. Therefore, eNOS uses BH4 cofactor as an electron donor to
rapidly reduce the oxyferrous complex, which can dissociate to
ferric heme and superoxide in BH4-depleted condition [32-34]. In
addition, this BH4 has been shown to play a role of “redox switch”
which means that it can attenuate superoxide release and promote
the formation of NO; and that an addition of 7,8-BH2 or sepiapterin
enhances superoxide release while inhibiting the production of NO
[35,36]. Thus, without this BH4 cofactor, eNOS shifts to produce
O2.-, a dangerous cytotoxic superoxide anion instead of NO; this
clinically deleterious phenomenon is known as eNOS uncoupling
[37-39]. It should be noted here that this superoxide anion can
be generated by both the heme in the oxygenase domain and the
flavins in the reductase domain, although FMN has shown to play an
insignificant role in eNOS uncoupling. In addition, eNOS uncoupling
can also be caused by heme directed inhibitors in addition to an
accumulation of endogenous eNOS inhibitors such as asymmetrical
dimethylarginine (ADMA) or eNOS S-glutathionylation [39]. The
consequences of having such a production of cytotoxic reactive free
radical via uncoupled eNOS can be dangerous to the CVS.
An intricate imbalance between the formation of highly cytotoxic
ROS and detoxification by low molecular weight antioxidants can be
a hallmark for most CVD. For example, oxidative stress induced by
eNOS uncoupling plays a notable role in the pathogenesis of arterial
hypertension, which is a highly prevalent cardiovascular risk factor
of morbidity and mortality in developed countries. The activation
and/or overexpression of eNOS allow vasodilation and regulation
of systemic blood pressure [40]. Administration of heparinbinding superoxide dismutase, a metalloenzyme that catalyzes the
dismutation of superoxide anion into molecular oxygen and H2O2,
which ultimately neutralizes the ROS and in turn, significantly
lowers arterial blood pressure in spontaneously hypertensive rats
[41]. Conversely, mice with a nonfunctional eNOS fail to induce
vascular endothelium-dependent relaxation [40]. As a result, eNOS
uncoupling is observed in isolated blood vessels from animals with
hypertension. Furthermore, vascular NADPH oxidase is a major
source of superoxide in angiotensin-II (AngII) treated hypertensive
mice [41]. Therefore, therapeutic interventions that would
attenuate or prevent eNOS uncoupling to normalize endothelial
function and improve cardiovascular function, in general, have
recently become a great interest in pharmacological research.

American Journal of Biomedical Science & Research

155

Am J Biomed Sci & Res

Copy@ Ally A, Nauli S

Figure 2: Schematic diagram of coupled versus uncoupled endothelial nitric oxide synthase or eNOS showing that uncoupled eNOS can
generate a highly toxic super radical as shown by the abbreviation O2-, the ion superoxide. Other abbreviations: O2 - Oxygen; NADPH
- Nicotinamide adenine dinucleotide phosphate hydroxide; NADP+ - Nicotinamide adenine dinucleotide phosphate; FAD - Flavin adenine
dinucleotide; FMN - Flavin mononucleotide; CaM - Calmodulin.

In addition, eNOS uncoupling may have a significant contribution
to the development of atherosclerosis. The vascular endothelial
cells have a critical role in not only the regulation of vascular tone
but also alterations in platelet function and aggregation, leukocyte
adhesion, plaque formation, development of atherosclerosis with
plaque, and ultimately the formation of a thrombus. For example,
in hypercholesterolemic apolipoprotein E knockout (ApoEKO) mice, atherosclerosis development accelerates without a
proper functioning eNOS [42], further suggesting that eNOS has a
protective role on the CVS. Endothelial dysfunction as a result of
eNOS uncoupling not only in coronary arteries but also within other
peripheral blood vessels as measured by acetylcholine-dependent
dilation has been shown to be an early predictor of CVD processes
leading to atherosclerosis [43]. Furthermore, eNOS dimerization
and uncoupling are also involved in the pathophysiology of arterial
stiffness [44] and patients with diabetic retinopathy [45]. Chronic
low-grade inflammation within the vascular endothelial cells and
the development of endothelial dysfunction with subsequent
cardiovascular maladies are closely related to oxidative stress
mediated via uncoupled eNOS enzyme [46]. In addition, immune
cells (white blood cells or WBC) can express high concentrations of
functional NADPH oxidases that can generate elevated levels of ROS
resulting in the induction of vascular oxidative stress [47]. Overall,
the above mechanisms that lead to oxidative stress vastly contribute
to the low-grade inflammation, particularly in the vasculature
of the older population [48]. The eNOS uncoupling undoubtedly
gives rise to oxidative stress, which has a negative impact on the
CVS [49,50], and is implicated in the pathogenesis of hypertension,
atherogenesis, and endothelial dysfunction.

eNOS Regulation
The expression and activity of the eNOS enzyme are carefully
controlled or regulated via numerous inter-related mechanistic
concepts occurring at the transcriptional, post-transcriptional, and
post-translational levels, in addition to its modulation by several
physiologic factors that in turn, have the potential to counteract
many of the age-related and/or lifestyle-related diseases
including cardiovascular and metabolic health. For example, oral
supplementation with L-citrulline that can be purchased over the
counter from any drug store or online, has been shown to lower
blood pressure in both resting conditions in adult humans, and
can also lower blood pressure during stress-induced pressor
effects [51]. This has been corroborated using animal studies that
L-citrulline can protect against the development of atherogenesis
in the endothelial cells of the blood vessel linings. In addition,
a previous study discusses whether L-citrulline reduces blood
pressure (aortic and brachial) following dietary L-citrulline
supplementation [52]. It has also been debated if oral administration
of L-citrulline effectively reduces blood pressure by approximately
7 mmHg via increasing the production of NO [53]. Furthermore, a
most recent meta-analysis of clinical trials shows that L-citrulline
supplementation reduces systolic blood pressure while there has
been a significant decrease in diastolic blood pressure in studies
that uses doses of ≥ 6 g/day [54]. Finally, it is postulated that oral
L-citrulline supplementation can enhance exercise performance
and recovery [55,56].
It is now known that the transcription factor for eNOS called
Sp1 which is also known as specificity protein 1, is a protein that
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in humans is encoded by the SP1 gene and is critically involved
in various cellular processes that may include cell differentiation,
cell proliferation, apoptosis, immune responses, chromatin
remodeling, and even DNA damage [57]. There are also posttranslational modifications such as phosphorylation, acetylation,
O-GlcNAcylation, or proteolytic processing that can, in turn,
considerably influence the activity of Sp1 via its modulation as
an activator or a repressor protein. Besides Sp1, there are other
factors that regulate transcription such as binding of factors like
Sp3, Ets-1, Elf-1, and also the YY1 to the eNOS promoter region and
followed by subsequent methylation of the DNA; this is a critical
mechanism of the eNOS transcriptional regulation [58]. There
are numerous regulatory factors such as H2O2 and more than 150
potential transcription factor binding sites for eNOS, such as eNOSdependent inhibition of the NF-κB subunit p65, that have been
shown to produce neuroprotective effects [59,60]. In addition,
eNOS is regulated post-transcriptionally via several mechanisms
such as modifications of the primary transcript, stability of the

and finally activates the calmodulin-binding domain of eNOS.
This ultimately facilitates the electron flux from the reductase to
the oxygenase domains of eNOS and produces NO. Furthermore,
post-translational modification via phosphorylation of the eNOS
enzyme is also equally critical for activation of the enzyme as it
enhances the active influx of electrons from the reductase to the
oxygenase domains in order to produce NO [73]. In addition to the
above mechanisms, protein kinase A (PKA) and protein kinase B
(Akt) activate eNOS by phosphorylating Ser1177 in response to
various stimuli and on the other hand, H2O2 and bradykinin will
activate eNOS via increasing Ser1177 phosphorylation and Thr495
dephosphorylation in order to produce NO [74-76]. In addition, the
levels of BH4 are significantly reduced in the plasma of spontaneously
hypertensive rats when compared to the WKY rat breed in the
aorta of insulin-resistant rats, and in deoxycorticosterone acetate
(DOCA)-induced-salt-treated hypertensive rats. A reduced eNOS
expression can decrease the production of NO as observed in adult
spontaneously hypertensive rats, however, other studies also show

If the bioavailability of NO as generated by the eNOS enzyme
is decreased there may be an increased risk of the development
of age-, environmental-, dietary-, and lifestyle-related diseases
such as hypertension, atherosclerosis, insulin resistance or type 2
diabetes, and other CVD [64]. Therefore, it appears that eNOS is a
crucial NOS isoform that regulates and modulates the function of
vasculature and the function of the CVS [65]. A thorough review of
the literature shows that the expression and activity of eNOS and
thus the downstream production of NO are initiated or modulated
by numerous stimuli, neurotransmitters, and even hormones that
are mediated via Ca2+-dependent or Ca2+-independent mechanisms.
For example, eNOS can be activated by shear mechanical stress
due to the flow of blood (laminar and turbulent) in a PKAdependent manner, bradykinin, histamine, and 17β-estradiol or
the major female sex hormone, and many other stimuli [66-72].
The mechanism of ACh-, bradykinin-, and histamine-induced
modulation of the eNOS activity is that they act on their respective
specific receptors on the endothelial cell membrane and increase
the intracellular concentration of Ca2+, which binds to calmodulin,

In addition to the above mechanisms, several pharmacological
agents can modulate the expression of eNOS. Angiogenesis or
formation of new blood vessels is involved in the growth of tumors
where both vascular endothelial growth factor (VEGF) and NO are
interchangeably involved. Aspirin, an over-the-counter medicine
that may be orally administered to prevent heart attack and stroke,
has been shown to inhibit eNOS [78]. Aspirin taken at bedtime
significantly diminishes plasma renin activity and excretion of
cortisol, dopamine, and norepinephrine in 24-hour urine that,
in turn, may reduce blood pressure [79]. However, there is also a
discrepancy in the literature about whether older publications
overstate the benefits of asprin [80]. Furthermore, angiogenesis
that is induced by the eNOS gene has been shown to be mediated
via the expression of VEGF in a rat model of hindlimb ischemia [81].
In addition, NO production and regulation of eNOS phosphorylation
are modulated via treatment with troglitazone, an activator of
peroxisome proliferator-activated receptors (PPARs) suggesting
the involvement of PPAR-gamma-dependent and PPAR-gammaindependent signaling pathways [82]. Therapeutic targeting of
up- and down-stream in the cascade of the eNOS/NO/sGC/cGMP
axis has been a recent focus of scientists aimed at the treatment
of several CVD (See Daiber et al., 2019 for a review [41]). Agonists
and antagonists of the sGC enzyme can be a future novel class of
“repair” medications that can modify the oxidatively damaged sGC
enzyme, and thereby can be prescribed for the treatment of not only
pulmonary hypertension or heart failure, but also in other situations
such as hypertension, erectile dysfunction, atherosclerosis,
restenosis, thrombosis, and inflammation [83]. Sepiapterin or

mRNA, cellular or subcellular localization, and the transport from
the nucleus to the cytoplasm [61]. Finally, modifications of eNOS
during its post-translational level are acylation of fatty acid, proteinprotein interactions, availability of the substrate and co-factors, and
phosphorylation. Furthermore, eNOS enzyme is inactivated because
of the strong and direct binding or interaction with caveolin-1 [62].
Lastly but not least, activation of eNOS is dynamically regulated and
modulated by multiple phosphorylation sites at tyrosine, serine,
and threonine residues [63]. Overall, it is now well-established that
the expression/activity of the eNOS isoform can be regulated by
several important mechanisms.

that endothelial dysfunction is associated with an elevated rather
than an attenuated eNOS expression [77].
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2-amino-6-[(2S)-2-hydroxypropanoyl]-7,8-dihydro-1H-pteridin4-one is a member of the pteridine class of organic chemicals
and is metabolized into BH4 via a salvage pathway that improves
endothelial function by preventing eNOS uncoupling in vascular
tissues in vivo [84]. Endothelial dysfunction in spontaneously
hypertensive rats is particularly based on vascular remodeling that
cannot be treated with antihypertensive medications. Therapeutic
treatment with the AngII subtype AT1-receptor-blockers, statins,
and organic nitrates that have antioxidant effects, significantly
improves the expression of GCH-1 or GTP cyclohydrolase I enzyme
which is a part of the folate and biopterin biosynthesis pathway that
can normalize BH4 levels, revitalize eNOS, and improve endothelial
function in pathological states such as diabetes, hypertension,
atherosclerosis, and nitrate tolerance [85,86]. AT1-receptor blocker
valsartan induces NO production via Src/PI3K/Akt-dependent
phosphorylation of eNOS, demonstrating vasoprotective AT-1
receptors in upregulating NO production [87]. These data are
supported by most recent studies suggesting that uninhibited AT1receptors can decrease eNOS activity [88]. Overall, AT1-receptor
participates in eNOS function, which in turn regulates blood vessel
homeostasis.
Hypercholesterolemic patients have impairment in the
endothelial function [89]. Because of its rigid ring structure,
cholesterol is an important component that dictates the fluidity
of the cell membrane. As cholesterol content in the cell membrane
increases, the flexibility of the plasma membrane decreases resulting
in altering the cascade of signaling pathways [90]. As a result,
cholesterol-induced impairment of NO production can therefore be
modulated by various factors including caveolin, AMPK, and NF-kB
[91,92]. Hypercholesterolemic patients carrying the CC genotype
for the g.-786T > C polymorphism when compared to TT carriers
receiving a protocol of statin therapy have more NO bioavailability
[93]. Furthermore, in both groups of hypertensive patients
carrying the TC/CC genotypes and the C allele for the g.-786T > C
polymorphism there are comparatively effective antihypertensive
responses with the administration of the ACEi enalapril [94]. Also,
male subjects with symptoms of erectile dysfunction who carry the
C allele for g.-786T > C eNOS polymorphism respond much better
when treated with sildenafil, the PDE-5 inhibitor [95]. The above
reports show that pharmacological agents such as statins, ACEi,
and PDE-5 inhibitors may have the ability to improve or resolve an
impaired production of NO in human subjects who carry the variant
allele/genotype for g.-786T > C eNOS polymorphism and indirectly
lessen the susceptibility of CVD.

Endothelial Nitric Oxide Synthase and the
Cardiovascular System
The previous sections discuss the role of eNOS in controlling
a healthy CVS and that a dysfunction of the eNOS enzyme is

correlated with a diverse pathogenesis of CVD. In the following
sections, the roles of eNOS in cardiac myocytes, heart functions,
vasculature, different regions of the brain, cardiovascular reflexes,
and cardiovascular regulatory pathways involving the autonomic
nervous system (ANS) will be elaborated.

eNOS in Cardiac Myocytes

The amount of NO as generated by eNOS has four mechanistically
different effects on the myocardial cells, such as (1) eNOS attenuates
the strength and frequency of cardiomyocyte contractility; (2)
eNOS enhances cardiac myocyte relaxation by increasing its
distensibility; (3) eNOS inhibits mitochondrial respiration; and (4)
eNOS improves the efficacy of myocardial oxygen consumption.
Overall, eNOS protein can partially inhibit cardiac myocyte
functions which may be eventually cardioprotective in both
physiological and pathological states. Most of the previous research
on eNOS and cardiac myocytes are focused on myocardial eNOS
involvement in the muscarinic regulation of inotropy; eNOS and
caveolin interaction in cardiac myocytes; role of PDE-5 inhibitors
on eNOS and myocytes; ROS and eNOS-dependent trafficking of
angiotensin-II (AngII) type 2 receptors (AT2R) in cardiac myocytes;
role of Ca2+ on eNOS activation; the interaction between purinergic
P2X4 receptors (P2X4R), a ligand-gated ion channel, with the
cardioprotective Ca2+-dependent eNOS enzyme; and how myocytespecific overexpression of eNOS protects myocardial ischemia/
reperfusion injury; among others.
The eNOS-induced NO production plays a critical role in the
regulation of coronary vasomotor tone, inhibition of platelet
aggregation, and prevention of cell adhesion to the vascular
endothelium under normal physiological conditions within
the CVS, in addition to modulation of myocardial contractile
function in vitro and in vivo [96]. However, in pathological states
like myocardial ischemia, there is a significant impairment of
endothelium-dependent coronary relaxation, altered myocardial
contractility, and the potential risk of life-threatening cardiac
arrhythmias. A previous report studies the role of eNOS in MI
followed by reperfusion injury by subjecting wild-type and eNOSdeficient mice to a 20-minute coronary artery occlusion followed
by 120 minutes of reperfusion, and indeed, eNOS gene deletion
has been shown to aggravate ischemic and reperfusion injury [97].
Another study demonstrates that upregulation of myocyte-specific
NO-cGMP generation provides significant cardio-protection against
MI and reperfusion injury due to blunted myofilament sensitivity
to Ca2+ and subsequent improvement of cardio-mechanical activity
[98]. With respect to the involvement of eNOS in the muscarinic
regulation of negative inotropy of the heart, eNOS overexpression
in left ventricular (LV) myocytes has been shown to enhance the
negative inotropic effects of muscarinic receptor stimulation both in
vivo and in cultured neonatal myocytes99. A previous investigation
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also reveals that myocardial eNOS is involved in both the
β-adrenergic-mediated positive inotropy and muscarinic regulation
of negative inotropy [99]. Another study also demonstrates that
muscarinic type-2 cholinergic receptors (M2AChR) signaling in
cardiac myocytes is targeted by the involvement of M2AchR with
sarcolemma caveolae and eNOS activation [99].

The interaction between eNOS and caveolin within cardiac
myocytes is also well-documented by the fact that eNOS is targeted
to plasmalemmal caveolae within endothelial cells. Caveolae are
specialized domains of the plasma membrane that host sequester
signaling proteins such as transmembrane proteins known as
the caveolins. In cardiac myocyte lysates, nearly all the eNOS is
immunoprecipitated by antibodies to caveolin-3 and, conversely,
by the eNOS antiserum immunoprecipitated caveolin-3. These
studies establish expression of eNOS in cardiac myocyte caveolae
and document tissue-specific and quantitative associations of eNOS
with caveolin [100]. Another study shows the cardiac myocyteprotective effects of microRNA-22, an anti-apoptotic agent, during
MI and reperfusion are mediated via disrupting the caveolin-3/eNOS
signaling [101]. On the other hand, the role of PDE-5 inhibitors on
eNOS and myocytes is also studied extensively, particularly following
the FDA approval of sildenafil. A previous report using reverse
transcription-PCR, western blots, and immunohistochemical assay
confirms the expression of PDE5 within mouse cardiomyocytes and
that sildenafil causes overexpression of mRNA and protein contents
of eNOS in the myocytes [102]. This sildenafil-induced protection
against necrosis and apoptosis is, however, reduced within the
myocytes of eNOS knock-out mice. In addition, the cytosolic Ca2+induced apoptosis within rat cardiomyocytes is mediated via
mitochondrial eNOS/NO/cGMP/protein kinase G pathways [103].
In this paragraph the interactions among eNOS, caveolin, and PDE5 inhibitors within the cardiac myocytes are highlighted.
A previous study demonstrates that pre-treatment of LV
myocardial cells with AT1R or AT2R antagonists and ROS
scavengers such as apocynin inhibits AngII-upregulation of the
nNOS protein, and that AngII elevates the eNOS-Ser1177 while
attenuating eNOS-Thr495 suggesting a concomitant activation of
eNOS [104]. Another study demonstrates in a genetic mouse model
that AT2Rs produce anti-hypertrophic results in cardiac remodeling
following a model of myocardial cryoinjury and the suggested link
is an over-expression of cardiac eNOS protein to AT2R activation
[105]. The role of Ca2+ on eNOS activation has also been extensively
investigated. Both NO and H2O2 play critical roles in physiological
and pathological states within the cardiac myocytes, however,
why or how the H2O2-modulated phosphorylation pathways
regulate eNOS in these cells is still incompletely understood. Early
studies document that H2O2 promotes Akt phosphorylation that is

dependent upon activation of the L-type Ca2+-channels and suggest
that Ca2+- and PKC-dependent signaling pathways are involved in
the modulation of cardiac myocyte eNOS activation by H2O2 [106],
thus further emphasizing the protective action of eNOS on the CVS.
On the other hand, endothelial NO production by eNOS requires
both Ca2+ signaling and Akt phosphorylation and can be modulated
by inhibiting or promoting either one of the pathways. The
activation of eNOS and subsequent NO production in endothelial
cells can be inhibited by mechanical sensors within the myocytes
involved in the NO production reaction cascade which is relevant
to heart diseases with significant clinical applications [106].
Finally, there is an interaction between P2X4 receptors (P2X4R)
which is a ligand-gated ion channel and the cardioprotective Ca2+dependent eNOS effects. The novel association between P2X4R
and eNOS suggests that cardiac-specific activation of eNOS is more
cardioprotective than an increased bioavailability of systemic eNOS
[107]. In the CVS, in addition to P2X4R, P2X7 plays major roles in
inflammation, cellular metabolism, apoptosis, and cellular death;
and thereby posing a serious concern in the development of MI,
stroke, and vascular diseases such as atherosclerosis, hypertension,
and thromboembolism [108].

eNOS, the Heart, and Cardiac Functions

Experiments with isoform‐specific inhibitors or genetic
deletion experiments have discovered specific regulatory/
modulatory roles for each of the three NOS isoforms that
are subserved by their subcellular localization and signaling
pathways in the cardiac muscle and the vasculature. Moreover,
using immunohistochemistry, western blot analysis, and NOS
catalytic assay, a previous study demonstrates the expression and
localization of eNOS in the myocardium and using eNOS mutant
(eNOS-/-) mice as an animal model to examine the role of eNOS
in cardiac function [109]. It is now well established that the
eNOS enzyme plays a critical physiological role in regulating and
modulating cardiac functions.

The nNOS, eNOS, and iNOS isoforms are located within the
sarcolemmal caveolae, sarcoplasmic reticulum (SR), T‐tubular
junctions, and the mitochondria within a cardiac myocyte. The
effects of the eNOS on cardiac functions including myocardial
contractility vary according to different stimuli such as myocardial
stretch due to increased blood volume or LV hypertrophy, oxidative
stress, β2/β3 adrenergic and/or M2 muscarinic receptor stimulation
that occur via the production of NO [110]. The anti‐adrenergic
inotropic effects following β3 adrenoceptor‐dependent activation of
eNOS and the production of NO are mediated via cGMP‐dependent
modulation of β‐adrenergic cAMP‐protein kinase A (PKA) pathways
mediated by L‐type Ca2+ channels, ryanodine receptor Ca2+‐release
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channel type 2 (RyR2), phospholamban, and the cardiac enzymes,
troponin I (TnI) and troponin C (TnC) [110]. In contrast, NO
produced by eNOS elicits positive inotropy, particularly following
myocardial stretch mediated via activation of protein kinase B
(PKB), nitrosylation of RyR2 and L‐type Ca2+ channels, activation
of adenylate cyclase, and RyR2 through phosphorylation of protein
kinase G (PKG). In hypertensive models of eNOS‐/‐ mice, there are
reports of reduced arteriolar density, reduced Ca2+ within the SR,
and increased expression of K+‐channels in ventricular myocytes
[111,112]. On the other hand, very high levels of eNOS expression/
activity and overproduction of NO in transgenic mice that have
overexpression of the eNOS gene show significantly attenuated
basal myocardial contractility that is most probably mediated
via desensitization of cardiac myofilaments to Ca2+. Overall, the
eNOS enzyme has been associated with both positive and negative
inotropic effects on cardiac functions. It should be mentioned here
that the cardioprotective and useful effects of physical exercise
following an attack of MI are crucially dependent on the expression
of endogenous eNOS within the heart and that the lack of one of the
eNOS alleles can nullify all the beneficial effects of regular exercise
[113].

The cardiac eNOS-derived NO and the endothelin-1 (ET-1)
systems are closely related, and both play a crucial regulatory
role in the modulation of cardiac physiology: An imbalance in
these two systems can be deleterious in eliciting several CVD such
as hypertension and stroke. One report investigates the cardiac
effects in mice models of excessive expression of ET-1 along with
lowered expression of eNOS while comparing LV hemodynamics
and cardiac morphology. The mouse models include wild-type
mice, ET-1 transgenic (ET+/+), eNOS knockout (eNOS-/-), and a
model of ET+/+ along with eNOS-/- mice. The results suggest that
overexpression of cardiac ET-1 along with simultaneous underexpression of eNOS modulate regulatory proteins and signaling
cascades that in turn, affect oxidative stress, myocardial strength
and contractility, and energy metabolism [114,115]. The uncoupling
of eNOS that results in a significant reduction of NO production will
have a potentiated elevation in myocardial superoxide. The resultant
effects are compromised coronary artery vasodilatation, elevated
amounts of myocardial collagen with decreased capillary/myocyte
ratio, stiffening of the heart, and end-diastolic LV stiffness [116].
It should be mentioned here that an episode of acute MI happens
in mice that lack all the three NOS enzymes [117]. Astragaloside
IV (AST, C41H68O14) is a small molecular saponin and the major
active component extracted from Astragalus membranaceus
(Fisch), a plant particularly valued in traditional Chinese medicine.
It has been shown to have anti-hypertensive, positive inotropic,
anti-inflammatory, anti-oxidative activities, and may block the
hypertrophy and apoptosis of myocardial cells following heart
failure [118]. This extract has been shown to reverse oxidative

stress-mediated injury, repair NO-signaling cascade, and improve
myocardial LV diastolic dysfunction in a rat model of metabolic
syndrome mediated via activation of the eNOS/NO/cGMP pathways
[118]. On the other hand, in humans, it has been reported that three
eNOS polymorphisms i.e., T-786C, VNTR4a/b, and Glu298Asp, and
their haplotypes have a better prognosis on the morbidity and
clinical outcomes in heart failure patients with systolic dysfunction
[119]. HSPA12B, an endothelial-cell-specifically expressed heat
shock protein, has been shown to reduce cardiac systolic dysfunction
and remodeling following an episode of MI in transgenic mice that is
mediated through an eNOS-dependent mechanism [120]. Finally, it
has been shown that the anti-hypertensive drug olmesartan (AT1R
antagonist) improves cardiac systolic dysfunction associated with
significant cardiac remodeling of Dahl salt-sensitive hypertensive
rats with end-stage congestive cardiac failure mediated via an
Akt/eNOS pathway [121]. In summary, the role of eNOS on cardiac
functions is well-established and that an impaired eNOS-derived
NO production exerts profound deleterious effects on several CVD
such as hypertension, stroke, and MI.

eNOS and the Vasculature

One of the most important functions of the eNOS enzyme is to
elicit the production of a sufficient amount of NO that regulates,
modulates, controls, and maintains the vascular tone of the CVS.
Diffusion of NO across the vascular smooth muscle cell membranes
activates the enzyme soluble guanylate cyclase (sGC) and catalyzes
the conversion of guanosine triphosphate into cyclic guanosine
monophosphate (cGMP) [122]. This cGMP is responsible for
activating protein kinase G (PKG) and eliciting phosphorylation of
cellular targets via reducing intracellular Ca2+ concentrations. The
ultimate result is vascular relaxation or vasodilation (Figure 3).

Recent advances in technology as well as imaging engineering,
such as contrast enhanced images for vascular phenotyping to
analyze defects in vascular perfusion/structure are emerging.
For example, the vascular tree of humans is a three-dimensional
organization and hence, two-dimensional assessments of the
vascular architecture do not provide enough information,
particularly about vessel thickness, volumetric abundance, and
connectivity. In addition, any histomorphometric analysis is also
shown to be destructive and much time consuming. Furthermore,
researchers have developed techniques using x-ray micro-computed
tomography (microCT) that will generate a three-dimensional
(3-D) vision of microscopic structures based on their attenuation
of x-rays [123]. Thereafter, modern polychromatic 3-D microCT
systems are invented that are capable of generating image volumes
as small as 1 μm with a meager 3-to-5-hour scan acquisition time.
Nowadays, contrast enhanced 3-D microCT has become a powerful
mechanistic tool for an enhanced telescopic visualization of any
vasculature.
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Figure 3: A schematic diagram of how eNOS via NO causes smooth muscle relaxation in vascular smooth muscle cells. Abbreviations: cGMP
– cyclic guanosine monophosphate, GTP – guanosine triphosphate, sGC – soluble guanylate cyclase, PKG – cGMP dependent protein kinase.

Using the 3-D x-ray microCT, investigators have shown that renal
cortical arteries of the kidneys in eNOS-/- mice have severe defects
in vascular perfusion and morphological structure [123]. Another
study also has quantified changes in eNOS mRNA levels throughout
the canine vasculature using competitive PCR assay [124], and that
the ACh- or bradykinin-induced vasodilation of forearm resistance
vessels in humans is mediated via the eNOS protein [125]. Indeed,
exercise training increases the amount of eNOS in the coronary
arterial microcirculation [126]. In addition, estrogen increases NO
release in human coronary arterial endothelial cells and is mediated
by the upregulation of eNOS [127]. Regular exercise and physical
activity in patients with coronary ischemic disease improve the
function of endothelial cells via increasing the phosphorylation
of the eNOS protein. In addition, regular exercise training elicits
an increased eNOS coupling that in turn, restores relaxation of
coronary arteries of heart failure rats [128]. It has been shown that
C-reactive protein (CRP), the prototypic marker of inflammation,
decreases eNOS expression along with its bioactive functions in
human aortic endothelial cells [129]. It has been widely known that
oxidative stress can lead to endothelial dysfunction and several CVD
risk factors that cause serious morbidity. Particularly, as mentioned
previously, endothelial function is dependent upon eNOS and that
a properly functioning eNOS activity within the endothelium is
critical for vascular integrity and homeostasis. Moreover, exposures
to loud noise, mental stress, and environmental factors represent

a strong trigger for oxidative stress that may ultimately lead to
atherosclerosis and endothelial dysfunction [41]. Thus, there has
been a new focus of therapeutic implications on eNOS function or
dysfunction in CVD including the importance of regular vitamin C
intake and/or selective antioxidant medications such as xanthine
oxidase inhibitors [41].

In addition to the coronary arteries and the aorta, previous
studies have shown in vivo adventitial expression of recombinant
eNOS gene in cerebral arteries [41]. Another study also investigates
the kinetics of NO elicited by eNOS following transient global
forebrain ischemia in mice that show the eNOS-derived NO
production in the striatum region of the brain after reperfusion is
closely related to eNOS activity [130]. It is now known that rupture
of an aneurysm of any cerebral blood vessel and subsequent
subarachnoid hemorrhage can cause fatal results, including
death, and Redundant and that one of the mechanisms of cerebral
aneurysm is a result of chronic inflammation in endothelial cells of
arterial walls due to an imbalanced hemodynamic force. It is known
that eNOS provides protection of the arterial wall layers from
vascular inflammation mediated via relieving hemodynamic force
and through the production of NO. A defective function of the eNOS
isoform could be compensated by upregulation of the nNOS enzyme
within cerebral arteries and that a complimentary balance between
eNOS and nNOS has a beneficial role in cerebral aneurysm [131].
Tea polyphenols are rich in green tea, which accounts for 30%-40%
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of the dry weight of tea leaves. Tea polyphenols mainly contain
four kinds of monomers: epigallocatechin-3-gallate, epicatechin,
epigallocatechin, and (-)-epicatechin-gallate. A recent study
shows that the epigallocatechin-3-gallate found in tea may reduce
neuronal apoptosis in a stroke rat model via PI3K/AKT/eNOS
signaling pathways [132]. Furthermore, another study suggests
that anticholesterolemic medications such as statins protect
against stroke by enhancing clot lysis via multiple mechanisms
involving the eNOS enzyme [133]. The widely prescribed antihypertensive drug, losartan, an AT1R blocker, can attenuate the
cerebral ischemia-reperfusion injury via PI3K/Akt-mediated
eNOS phosphorylation [134]. A recent study investigates the role
of vitamin D3 in the upregulation of the eNOS protein within the
endothelium of cerebral arteries after subarachnoid hemorrhage
in rats, and indeed, this vitamin can reduce the cerebral artery
remodeling through VDR/AMPK/eNOS dimer phosphorylation
pathways [135].
The Ca2+ channel and Ca2+signaling also play an important role
in mediating the eNOS activity. Several transient receptor potential
(TRP) cation channels have been shown to regulate eNOS activity
and NO production, as well as their role in CVD. TRPP2, also known
as polycystin-2, is regulated by fluid-shear stress, and it initiates
a signaling pathway cascade of Ca2+, calmodulin, Akt/PKB, and
PKC [69,70]. Dysfunction in sensing the shear-stress or signaling
cascade results in vascular hypertension [66,67]. The TRP subfamily
V member 1 (TrpV1) or Subfamily A Member 1 (TRPA1) is also
involved in the regulation of eNOS activity. The Ca2+ influx triggered
by TRPV1 activation in endothelial cells can induce the activity
and expression of eNOS [136]. TRPV1 agonism inhibits endothelial
cell inflammation via activation of eNOS/NO pathway and inhibits
hypertension-induced cellular inflammation in endothelial cells via
Ca2+/PI3K/Akt/eNOS/NO pathway [137].

The eNOS-derived NO has a critical role in maintaining vascular
function, exerting an antithrombotic action, and that an attenuated
expression of eNOS is closely related to stroke and Alzheimer’s
disease (AD), the most common type of dementia associated with
neurovascular dysfunction. A previous study indeed shows that a
deficiency of eNOS using a heterozygous eNOS+/- mice to mimic
partial deficiency of eNOS, causes spontaneous thrombotic cerebral
infarction and signs of cognitive impairment [138]. Overall, it can
be summarized that the eNOS protein has a very critical function in
vascular homeostasis and that a lack or defective eNOS can lead to
serious pathological consequences for developing CVD.

Endothelial Nitric Oxide Synthase and the
Nervous System
One of the multiple actors impinging on the nervous system is
NO that plays an extensive role in both the central and peripheral

nervous systems. All the three isoforms, (eNOS, nNOS, and iNOS) are
intricately involved in both normal physiological and pathological
functions of the central nervous system related to the control of the
CVS and diseases such as hypertension and stroke.

eNOS and the Central Nervous System

The glial cells as well as the pericytes surrounding the cerebral
blood vessels contain guanylyl cyclase (GC) that is stimulated by
eNOS-derived NO release from endothelium. The eNOS protein is
abundant in both cerebral vascular endothelial cells and motor
neurons; and in normal physiological processes, the eNOSderived NO regulates blood flow, circulatory changes, and acts as a
messenger during long‐term potentiation (LTP). On the other hand,
in pathological situations such as hypertension and cerebrovascular
accidents, the function/expression/activity of the eNOS isoform
is impaired that may contribute to a reduction in blood flow,
dysfunctional oxygen/metabolites delivery, massive release of Ca2+,
glutamate, ROS, super radicals, and other toxicological agents from
the brain tissues in association with a disturbed blood brain barrier
[1,139].

The eNOS isoform via producing NO also regulates the
microcirculation within the cerebral vessels, inhibits platelet
aggregation, and blocks leukocyte adhesion and migration [140,141].
Under physiological conditions, the concentration of NO molecules
fluctuates within a range of low values that are generated by nNOS
and eNOS, however, because of its Ca2+‐independent activation, the
iNOS isoform can produce a large amount of NO that is about 100 to
1000 times higher that can turn into a toxic super radical [142,143].
Thus, if a question arises, “Is NO a friend or a foe”, the answer is
both. Nitric oxide in moderate amounts can be neuroprotective
while NO in large concentrations will be neurotoxic or cytotoxic.
Interrupting the gene that encodes eNOS will lead to spontaneous
systemic and pulmonary hypertension and will inhibit growth
factor (GF)‐mediated angiogenesis in experimental mice [144,145].
Even in animal models of inflammatory disease, the disruption of
the blood brain barrier is mediated by dysfunctional eNOS activity
[146] and that eNOS is also impaired during systemic infection,
which may lead to a dysfunctional cerebral microcirculation [147].
In addition to the role of the nNOS isoform on the CVS1, many
studies have demonstrated the localization of the eNOS enzyme
within different regions of the brain, particularly the nucleus
tractus solitarii (NTS), the rostral ventrolateral medulla (RVLM)
and the caudal ventrolateral medulla (CVLM), major areas that are
closely related to the central regulation of circulation and reflexes
such as the baroreflex and the Exercise Pressor Reflex [1,139]. The
laboratory of Hirooka et al. has developed a novel in vivo technique
for an effective eNOS gene transfer into the NTS of conscious rats and
performed several studies to determine the effects of eNOS within
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the NTS on the sympathetic autonomic nervous systems (SANS)
[148-150]. In addition to the NTS, studies with eNOS and its effect
on the RVLM in both acute and anesthetized models have shown
both sympatho-excitatory and sympatho-inhibitory responses
[148-150]. Overexpression of the eNOS isoform within the RVLM
produces a prolonged sympatho-inhibitory effect. Microinjection of
bicuculline, a γ-amino butyric acid (GABA) receptor antagonist, into
the RVLM increases blood pressure and an overexpression of eNOS
in addition to a rise in localized GABA concentration [151].

Numerous mechanisms, neurotransmitters, receptors, and
pathways are involved within the RVLM and the CVLM regions of
the medulla that regulate the CVS. Overall, the NO as generated
from an overexpression of the eNOS protein within the RVLM is
known to cause sympathoinhibition via modulating GABA release.
Previous research results also corroborate with the above findings
where microdialysis of the eNOS blocker, L-N(5)-(1-iminoethyl)ornithine (L-NIO; 10 µM), into the RVLM in anesthetized rats did
not change the resting blood pressure, heart rate (HR), glutamate
concentration, and GABA levels; however, a higher 50 µM dose of
L-NIO administered into the RVLM increases blood pressure, HR,
and localized glutamate levels while decreasing GABA levels [152].
Totally opposing effects are observed when the eNOS antagonist
is administered into the CVLM [152]. Overall, it is now known
that cardiovascular control mechanisms within the medulla
are maintained by a balance between excitatory and inhibitory
interactions among eNOS, glutamate, and GABA [139]. Moreover,
the central nervous system exerts profound cardiovascular
effects via the autonomic nervous system, and the following
subsections will focus on the role of eNOS on both the SANS and the
parasympathetic autonomic nervous systems (PANS) that regulate
and control the CVS.

eNOS and the Sympathetic Autonomic Nervous System

The SANS and the CVS are intrinsically linked through nerves
such as the cardiac sympathetic nerves, various adrenergic
receptors such as α and β adrenoceptors, and neurotransmitters
or neurohormones such as epinephrine and norepinephrine.
In addition, the SANS sends its sympathetic fibers to major
blood vessels, adrenal glands, and the kidneys [153]. As a result,
the function of SANS is more extensive with both direct and
indirect control of most of the cardiac and vascular functions.
When activated, the SANS releases norepinephrine that binds
to β-adrenergic receptors and activates adenyl cyclase. Through
downstream signaling cascade, HR rises due to the increase of
diastolic depolarization in the sinoatrial or the sinus atrial (SA)
and atrioventricular (AV) nodes, thereby regulating both cardiac
rate and stroke volume [153]. Besides its cardiac function,
norepinephrine released from the sympathetic axon can also bind

to α1- or β2-adrenergic receptors on vascular smooth muscle
cells resulting in vasoconstriction or vasodilation, respectively, in
addition to maintaining a resting vascular tone [154]. Thus, there is
a pivotal role of the SANS in cardiac and vascular functions.

In the brain, NO is known to modulate the activities of the SANS
and to regulate cardiovascular activities such as control of mean
atrial pressure (MAP) and HR fluctuations [1,139]. In addition,
acting within the paraventricular (PVN), supraoptic nuclei (SON)
of the hypothalamus, and the posterior hypothalamus, NO has
been shown to be an important neurotransmitter regulating
the neurohumoral control on the CVS [155]. Along with nNOS, a
significant amount of eNOS is expressed in the hypothalamic PVN
and SON. Moreover, the basal bioavailability of NO in the PVN is
maintained by both the eNOS and nNOS isoforms. However, NO
synthesis by eNOS primarily contributes to the tonic NO levels due
to its ability to maintain a constant NO bioavailability regardless
of cytosolic Ca2+ concentrations. Moreover, eNOS-derived NO
regulates the neuronal activity of the hypothalamic PVN and
modulates sympathoexcitatory effects on the circulation. Reduced
NO levels within the PVN can increase sympatho-excitation in
rats with heart failure155. Substantial vasoconstriction can also
occur if the sympathetic outflow is overactivated153. In addition,
hyperactivity of the SANS can lead to arterial hypertension and
heart failure and plays a significant role in the pathogenesis of CVD
[156]. Before exploring the relationship among NO, the SANS, and
CVD such as hypertension or heart failure, the regulatory effect of
NO on the SANS via the medullary cardiovascular control regions
like the RVLM and the CVLM is discussed in the following sections.
The RVLM is a vasomotor center and is known as the pressor
region that regulates the sympathetic outflow from the brain
while the CVLM is a depressor region [157]. Through the NTS
and the PVN in the hypothalamus, the RVLM receives stimulus
from baroreceptors, chemoreceptors, and visceral receptors. An
overexpression of eNOS in the RVLM results in an increase in local
NO production via modulating the release of GABA and glutamate
and can be sustained for several days [158]. To further elaborate,
NO activates N-methyl-D-aspartate (NMDA) receptors localized
on the pre-sympathetic neurons of the RVLM and triggers the
release of GABA. As mentioned above, the production of NO from an
overexpression of eNOS in the RVLM exerts a sympathoinhibition
effect. In contrast, sympathoexcitation in the RVLM is mediated
by oxidative stress that can be produced from the activation of
the AT1R/NADPH oxidase within the RVLM. Moreover, oxidative
stress in the RVLM can also come from alternative sources such as
xanthine oxidase, mitochondria, NADPH oxidase, and uncoupled
eNOS. Nonetheless, AT1R antagonists in the RVLM elicit an
inhibitory effect on the SANS. Therefore, the most notable source
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of oxidative stress in RVLM might come from AT1R/NADPH oxidase
instead of the other sources as mentioned above [158].

Activation of the SANS increases NO release that can be
modulated by altering sympathetic nerve activity that in turn,
contributes to an increased blood flow during and after exercise.
In both animal and human studies, sympathetic nerve activity
can stimulate NO release from eNOS and also from the nNOS
protein [159]. This production of NO by eNOS contributes to
functional sympatholysis or local attenuation of SANS-mediated
vasoconstriction in exercising muscle and/or to direct vasodilation
via β2 adrenoceptors in the skeletal blood vessels during exercise.
It has been known that NO derived from eNOS regulates blood
flow under physiological conditions in humans, however, human
studies with a selective nNOS inhibitor, SMTC, demonstrate that
the basal vascular tone in forearm and coronary circulatory
vasculature are regulated via the nNOS isoform, whereas
eNOS is responsible for the vasodilation in response to either
pharmacological manipulations or stimulus from shear stress
[160,161]. Another study using non-selective NOS inhibition with
L-NMMA shows a potentiated vasoconstriction of forearm blood
vessels in response to low body negative pressure, suggesting that
reflex sympathetic vasoconstriction is opposed by eNOS-derived
NO [162]. It is possible that the potentiated vasoconstriction due
to sympathetic stimulation is because norepinephrine release
in response to low body β as previously described in animal and
human studies [159]. Thus, eNOS-derived NO can attenuate α1adrenergic receptor mediated vasoconstriction. Another study has
shown that epinephrine significantly increases eNOS expression
or activity in cultured bovine aortic endothelial cells (BAEC) and
that this activation is associated with elevated phosphorylation of
eNOS at Ser(1179) along with an attenuated eNOS phosphorylation
at the inhibitory phosphoresidues Ser(116) and Thr(497) [163].
Epinephrine also activates the small G protein Rac1 and protein
kinase A which can be antagonized by the β3-adrenoceptor
antagonist, SR59230A. Moreover, regular exercise training can
cause eNOS to be less coupled and elevate NOS-dependent
superoxide levels in β3- adrenoceptor knock-out mice [164]. It has
been shown that supplementing those β3-adrenoceptor knockout mice with the eNOS coupler BH4 during the exercise training
protocol can prevent an attack of MI. Thus, regular exercise has a
beneficial role by protecting the heart in the setting of myocardial
ischemia/reperfusion injury via activation of the eNOS protein
through a β3-adrenoceptor-AMP-activated protein kinase signaling
pathway [164].

eNOS and the Parasympathetic Autonomic Nervous
System

The PANS role on the CVS largely includes the functions of
the vagus nerve, the neurotransmitter acetylcholine (ACh), and

muscarinic receptors, particularly the M2-subtype within the
SA node in the heart. Both the SANS and PANS have their mutual
influence on the heart; activation of the SANS increases HR while
stimulation of the PANS causes bradycardia. The PANS also has
parasympathetic fibers that innervate small blood vessels outside
of the heart, however, the primary function of the PANS is limited
to controlling the cardiac function via regulating the HR and
maintaining a vascular tone [153]. Although stimulation of the
PANS causes bradycardia, it plays a minor role in regulation of
blood pressure when compared with the SANS, and thus there
are few studies that target the PANS as a treatment strategy for
hypertension and other CVD. Nevertheless, a decrease in PANS
activity is associated with essential hypertension in humans. A
dysfunctional PANS can reduce HR variability and is associated with
CVD such as MI, heart failure, and cerebrovascular accidents [165].
In addition, exercise-induced potentiation of basal parasympathetic
tone may have a beneficial effect in alleviating hypertensionassociated end-organ damage [165].

In order to stimulate the PANS, there have been some
experiments where electrical nerve stimulators are implanted
on the cervical vagus nerve to chronically stimulate it. Moreover,
there is a hypothesis that this chronic vagal nerve stimulation
(VNS) can reduce the progression of end-organ damage in
hypertensive rats. Chronic VNS only affects endothelial function
and aortic stiffening but has no role in cardiac functions or vascular
hypertrophic changes166. The study also demonstrates that the
gradual reduction in NO-dependent relaxation of the long posterior
ciliary artery in sham-stimulated rats that are on a high-salt diet is
prevented in rats with chronic VNS, and this improved endothelial
function is attributed with a greater activity and phosphorylation of
the eNOS protein [166]. The PANS neurotransmitter ACh produces
an indomethacin-sensitive relaxation in the mesenteric arteries of
knockout NOS (-/-) mice while the resting membrane potential of
vascular smooth muscle cells derived from the coronary arteries
is considerably less negative in the eNOS (-/-) mice [167]. The
activity/bioavailability of coupled eNOS and subsequent generation
of NO can be either initiated or enhanced by several stimuli that
include Ach [168]. In hypertensive patients or even people with
prehypertension, the NO-mediated relaxation in response to ACh is
blunted [169]. This is also true for normotensive and hypertensive
rats suggesting that the reduced NO bioavailability can be attributed
to a dysfunctional eNOS-derived decreased NO production and/or
an increased NO degradation [170]. It is known that regular exercise
is a nonpharmacological therapy for not only prevention but also
for treatment of CVD because of its beneficial milieu in improving
vascular function. Indeed, exercise training can induce eNOS
coupling that in turn, can restore relaxation in coronary arteries of
heart failure rats [170]. Overall, the interaction between the PANS
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and its neurotransmitter ACh and the eNOS isoform contributes to
healthy cardiovascular functions.

Endothelial Nitric Oxide Synthase
Cardiovascular Autonomic Reflexes

and

The cardiovascular autonomic reflexes are responses that have
profound physiological impact on the cardiovascular structures
and functions either through direct neural innervation or via
modulating the release of chemicals/hormones or substances such
as epinephrine, renin, and anti-diuretic hormone. Cardiovascular
reflexes regulate and maintain bodily homeostasis during normal
day-to-day activities like sleep, exercise, walking, running, rage,
anger, or other situations. The two main cardiovascular autonomic
reflexes are the baroreflex and the Exercise Pressor Reflex.

eNOS and Baroreflex

The arterial baroreceptor reflex, or baroreflex, is the most
important mechanism for minute-to-minute regulation and

maintenance of blood pressure that buffer the continuous
fluctuations/changeability of blood pressure due to posture,
exercise, pain, emotion, and other circumstances. Several
neurological situations can modulate the central and/or peripheral
baroreflex mechanisms that in turn, may manifest with paroxysmal
hypertension, a reflex syncope, or even neurological orthostatic
hypotension. One example of the baroreflex-mediated cardiovascular
homeostasis is that if the blood pressure rises, the PANS activity is
increased along with a decrease in the SANS reactivity. The major
baroreceptor reflex pathway exists within the medullary region of
the brainstem, i.e., the NTS, the RVLM, and the CVLM [157]. The
overexpression/activity of eNOS within the RVLM or NTS decreases
blood pressure, HR, and renal sympathetic nerve activity that are
augmented in stroke-prone spontaneously hypertensive rats
[150,158]. An increase in eNOS-derived NO production within the
RVLM significantly improves the impaired baroreflex regulation of
HR in stroke-prone spontaneously hypertensive rats and that one
of the mechanisms is related to cardiac sympatho-inhibitory effects
of NO [150]. It is now well-established that the RVLM neurons can
regulate the activity of the SANS via both baroreflex-dependent
and baroreflex-independent mechanisms. These corraborate with
other data on central and peripheral neural mechanisms that
regulate arterial baroreceptor reflex and mechanisms of adaptation
and resetting of the baroreceptor reflex [166,171]. However,
endogenous NO production by the eNOS protein within the RVLM
is impaired or insufficient that can compensate for the abnormal
baroreflex function in hypertension, although it is known that the
RVLM neurons receive a tonic GABAergic input that is partially
dependent on baroreceptor inputs and partially independent [171].

The baroreceptor-regulated blood pressure buffering effect
of endogenous NO is shown to be mediated by the eNOS protein
and that eNOS-derived endothelial NO is most effective in
buffering blood pressure oscillations via modulating the baroreflex
mechanisms in experiments with conscious wild-type and eNOS
mutant mice [172]. However, the same study cannot find any
differences in baroreceptor reflex sensitivity between eNOS
mutant and wild-type control mice; thus, the question is why the
baroreceptor reflex does not cancel the enhanced blood pressure
changeability in eNOS knockout mice. It may be possible that the
higher variability in blood pressure changes as observed in eNOS
knockout mice is partially compensated for by the baroreceptor
reflex and is dependent on a functional eNOS system. An endogenous
eNOS expression or activity within the NTS has been suggested to
play a role in long‐term sensitivity of baroreceptor reflex gain and
a study has determined that chronic inhibition of eNOS activity
within the NTS enhances baroreceptor reflex in experiments with
conscious rats [173]. Another report using adenoviral‐mediated

gene transfer of a dominant negative protein to genetically disable
eNOS in the NTS shows that the effect of an administration of AngII
on the baroreceptor reflex is blocked, which further validates that
the action of AngII is mediated by activation of the eNOS protein
[174]. Indeed, the NTS modulates both the baroreceptor and the
Exercise Pressor Reflex via a NO-dependent mechanism within
the NTS [175]. Furthermore, local application of the non-specific
NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), to the
carotid sinus abolishes the inhibition of baroreceptor activity and
the increases in carotid artery diameter in eNOS-transduced carotid
sinuses suggesting that adenoviral-mediated gene transfer of eNOS
to carotid sinus adventitia causes a NO-dependent inhibition of the
baroreceptor mechanism, including a reset of the baroreceptor
reflex in response to high blood pressure [176]. Because the
baroreflex plays a critical role in regulating/controlling short
term blood pressure changes, there are polymorphisms identified
within the eNOS gene, i.e., the CYP11B2 and the B2R genes, that are
associated with 16% of the variation in baroreflex sensitivity [177].

eNOS and the Exercise Pressor Reflex

Static exercise or static muscle contraction raises MAP, HR,
myocardial contractility, cardiac output, and sympathetic nerve
activity [139,157,178,179]. The exercising muscles activate the
group III and IV muscle afferents within the spinal cord, transmit
the information to different parts of the brain, particularly to the
neurons in the medulla oblongata of the brain stem, however, the
main areas of integration of the signals are the RVLM or the pressor
region and the CVLM or the depressor area. A plethora of molecular
mechanisms, neurotransmitters, receptors, and reciprocal
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pathways are involved within these two RVLM and CVLM areas
as well as other higher regions of the brain that are collectively
known as the “central command”. Pharmacological manipulations
by L-arginine, the NO precursor, or by nNOS, iNOS, and eNOS

antagonists are involved in the modulation of the Exercise Pressor
Reflex [1,180]. A brief schematic diagram of the Exercise Pressor
Reflex is shown in (Figure 4).

Figure 4: A summary of the Exercise Pressor Reflex arc reflecting major neurotransmitters and regions of the brain that are involved.
Abbreviations: NO - nitric oxide; eNOS – endothelial nitric oxide synthase; iNOS – inducible nitric oxide synthase; nNOS – neuronal nitric oxide
synthase; RVLM – rostral ventrolateral medulla; CVLM – caudal ventrolateral medulla; IML – intermediolateral column of the spinal cord.

The nNOS isoform within the RVLM and the CVLM differentially
modulates cardiovascular responses during static exercise
[139,152]. Moreover, the modulation of the exercise pressor reflex
by nNOS is attributed to differential alterations in glutamate and
GABA neurotransmission within the RVLM and CVLM, and that
blockade of nNOS can also modify the expression of the nNOS
isoform within the RVLM and CVLM [181]. A similar modulation
of the exercise pressor reflex by the iNOS isoform via glutamate,
GABA, and expression of the iNOS protein is regulated within the
RVLM and CVLM1. The eNOS protein has also been implicated in the
mechanism of the exercise pressor reflex. Overexpression of eNOS
protein by elevated eNOS causes hypotension and bradycardia
suggesting its role in decreasing the activity of the SANS150.
Moreover, overexpression of eNOS within the RVLM attenuates
MAP, HR, and sympathetic nerve activity, and these effects are
more pronounced in stroke-prone hypertensive rats. An increase in
blood eNOS levels decreases plasma cholesterol values and offers
protection against atherosclerosis or other CVD, conditions that
can be prevented by regular exercise [182]. The eNOS differentially
alters MAP and HR changes in response to static exercise via
modifications of glutamate and GABA concentrations within the

RVLM and CVLM, and that eNOS antagonism by pharmacological
agents also modulates the expression of the eNOS isoform within
the RVLM and CVLM [1,131]. Administration of an eNOS blocker,
L-NIO at a dose of 10 µM, into the RVLM in anesthetized rats
potentiates the increases in MAP and HR responses during static
muscle contraction and opposite effects happen when the drug is
microdialyzed into the CVLM152. The 10 µM L-NIO did not change
the basal blood pressure or HR, however, a higher 50 µM dose of
L-NIO administered into the RVLM increases resting basal blood
pressure. Simultaneously, microdialysis of L-NIO into bilateral
RVLM for 120 minutes attenuates the abundance/expression of
eNOS as measured from the same area183. Thus, the autonomic
and cardiovascular reflex mechanisms within the medulla
oblongata to achieve a physiological homeostasis are regulated
via a balance of an excitatory and an inhibitory interaction among
the eNOS, nNOS, and iNOS proteins and their synthesis of NO, in
addition to glutamatergic and GABAergic neurotransmission
[1,139]. However, other molecular and cellular changes may also
occur within the VLM following focal cerebral ischemic injury that
can further elucidate the pathogenesis, circulatory manifestations,
and treatment strategies of stroke, including the potential benefits
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of exercise. Exercise is recommended after stroke as a part of
rehabilitation, yet the interaction between exercise and brainstem
mechanisms mediating cardiovascular activity is still poorly
understood. It should be noted here that the NTS is also involved
in the modulation of the Exercise Pressor Reflex functions via NO/
cGMP pathways within the NTS [175].

Endothelial nitric oxide
Cardiovascular Diseases

synthase

and

Numerous studies and research are being performed to
delineate the mechanisms of the nNOS/eNOS/iNOS/NO/cGMP/cGC
pathways and how this highly reactive gas known as NO that can
change into a free radical is involved in regulation and pathogenesis
of the CVS (Figure 2) [184].

eNOS and Hypertension

Hypertension is typically asymptomatic. However, some
people with hypertension may have headaches, lightheadedness,
vertigo, tinnitus, altered vision or fainting episodes. Hypertension
with certain specific additional signs and symptoms may suggest
secondary hypertension, i.e., hypertension due to an identifiable
cause such as pheochromocytoma or kidney disease. Hypertension
occurs in ~10% of pregnancies and can be associated with
pre-eclampsia which may be either asymptomatic or with
manifestations of headache, visual disturbance (“flashing lights”),
vomiting, pain over the stomach, and swelling. The eNOS plays a
crucial role in blood pressure regulation and that it is mediated
via eNOS-derived NO production resulting in vasodilation through
cGMP-dependent protein kinase (PKG) activation within the
vascular smooth muscle cells (VSMCs; Figure 3) [66,67,185].
Essential hypertensive patients do experience dysfunction of NOmediated vasodilatation in several arterial trees such as the brachial,
coronary, and renal arteries, and that the transport of L-arginine
is dysfunctional in hypertensive or even normotensive human
subjects who have a family history of essential hypertension [186].
The importance of L-arginine cannot be underestimated because
oral supplementation of L-arginine benefits in restoring endothelial
function in hypertensive patients by modulating the release of
neuroendocrine hormones such as catecholamines, altering plasma
renin-AngII activity, and decreasing plasma aldosterone levels
[187]. Measurement of MAP in the eNOS deficient mice shows a 20
mmHg higher MAP when compared to its wild type variants [145].
Thus, a thorough understanding of the molecular mechanisms of
eNOS dysfunction in hypertension may lead to further research
and development of novel therapeutic agents that will manage
hypertension, the “Silent Killer” disease. To elaborate further, there
are several mechanisms that have been proposed for eNOS-derived
NO deficiency in hypertension. The eNOS is important for a healthy
vasculature that not only prevents hypertension but also stops the

process of atherosclerosis [188]. A deficiency of NO by superoxide
anion will cause endothelial dysfunction and hypertension. All of
the following e.g., NADPH oxidase (NOX1), xanthine oxidase (XO),
uncoupled eNOS, mitochondria, and cyclooxygenase (COX) produce
ROS [189]. COX-2 generates oxidative stress within resistance
arteries of patients suffering from essential hypertension that in
turn, may lower the bioavailability of NO [190]. Furthermore, COX2-derived prostaglandin F(2α) is linked to endothelial dysfunction
in renovascular hypertensive rats. Finally, the ROS produced by
NOX is shown to increase expression of COX-2 via a p38 MAPKdependent mechanism that in turn, causes uncoupling of the eNOS
protein [191].
Angiotensin II causes vasoconstriction and an increase in
blood pressure, and its plasma concentrations are consistently
elevated in hypertensive patients [192] and AT1R antagonists
such as Valsartan are highly effective in lowering blood pressure
to normal levels. One study demonstrates that eNOS uncoupling

leads to the development of hypertension in mice receiving an
infusion of AngII [193]. Aneurysm mediated by eNOS uncoupling
can be reversed by the administration of folic acid in AngII-infused
apolipoprotein E (apoE) null mice because of the restoration
of endothelial dihydrofolate reductase (DHFR) expression and
activity [194]. Because the uncoupling of eNOS is a pathogenesis
of essential hypertension, any therapeutic target that is able to
restore eNOS coupling activity in blood vessels can be a part of the
treatment protocol for hypertensive patients. Anticholesterolemic
medications such as statins, anti-hypertensive drugs such
as losartan, and even vitamin D3 are beneficial to a healthy
vasculature. BH4 deficiency plays a key role in determining eNOS
uncoupling-dependent hypertension and supplementation with
BH4 may have a beneficial therapeutic effect that will restore
endothelial dysfunction in hypertensive patients via endotheliumdependent vasodilation [195]. Moreover, ascorbic acid or vitamin
C can maintain BH4 levels during situations of increased vascular
oxidative stress, and that this vitamin C can prevent uncoupling
of eNOS by ONOO-196. Further, in genetic models of hypertensive
rat, vitamin C can improve endothelial function via restoration
of the eNOS isoform [197]. Finally, oral administration of BH4
can attenuate the production of vascular ROS and lowers blood
pressure in DOCA-salt hypertensive rats [198].

eNOS, Arteriosclerosis, and Myocardial Infarction

Myocardial infarction or MI is commonly known as heart
attack and happens when there is a reduced coronary blood flow
(ischemia) or a complete block in the blood supply to a part of
the heart resulting in damage or necrosis of the heart muscle or
myocardium [199]. The most common symptom is chest pain or
discomfort which may radiate to the shoulder and arm that may
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end up with heart failure, an irregular heartbeat such as atrial
fibrillation, cardiogenic shock or cardiac arrest. Most MIs occur due
to coronary artery disease and a complete blockage of any branch
of the coronary artery due to a rupture of an atherosclerotic plaque
is commonly the underlying mechanism of an MI. Thus, MI and
atherosclerosis are very closely related to each other [199].

The role of oxidative stress in the progression and pathogenesis
of CVD has been shown in an experimental animal model of
hypercholesterolemia [200]. Other studies using genetic animal
models such as knockout mice also report how ROS is critically
engaged in the development, pathogenesis, and consequences of
several CVD like arteriosclerosis that may lead to an event of MI
[201]. In mice, genetic deletion of the NADPH oxidase subunit
p47phox can restore NO bioavailability in coronary arteries,
prevents the production of ROS, and at the same time benefits
cardiovascular functions by increasing the survival rate by 20%
in the event of post-MI circumstances [202]. Deletion of the
NADPH oxidase subunits p47phox reverses hypertension to
normal values and restores endothelial health in AngII-infused
hypertensive mice [203]. In addition, in mice with a partial deletion
of the mitochondrial superoxide dismutase (MnSOD+/-) there is an
elevated susceptibility of mitochondrial oxidative stress along with
a dysfunctional endothelial cell layer in the coronary arteries [204].
Likewise, a totally deficient mitochondrial superoxide dismutase
enzyme will make mice at a higher risk of endothelial dysfunction,
and deletion of the glutathione peroxidase-1 will cause significant
atherosclerosis and plaque formation leading to thrombosis in
ApoE-/- mice [205]. If NOX1 has an increase in its activity and
is overexpressed, there will be elevated blood pressure [206].
Several interleukins are also involved in the link between eNOS and
arteriosclerosis. For example, IL-17A plays an active role in vascular
inflammation that will lead to atherosclerosis and hypertension,
including MI [207]. Another study also shows that IL-17A plays a
critical role in the onset and progression of AngII infusion-induced
vascular dysfunction [208]. Together, many studies demonstrate
that eNOS has a crucial role in causing oxidative stress that in turn,
may lead to the development of several CVD such as arteriosclerosis
and MI.
Myocardial infarction causes significant LV remodeling,
cardiomyocyte swelling or hypertrophy, a decrease in capillary tree,
an increase in fibrosis, apoptosis, necrosis, LV systolic dysfunction,
and LV diastolic imbalance. The beneficial effects of regular exercise
for a healthy CVS are well established and even exercise or static
exercise is a part of the treatment protocol following a cardiovascular
injury including post-MI. There are numerous studies of the
beneficial effects of exercise including in a post-MI situation, and
there is evidence that this positive effect of exercise is mediated
via an increase in eNOS activity. Exercise training by eNOS +/+ MI

mice totally reverses the fibrosis and apoptosis in the myocardium
and decreases LV systolic dysfunction that are not seen in eNOS
+/- and eNOS -/- mice [113]. AMP-activated protein kinase (AMPK)
is a protein kinase-sensing metabolite and if activated after MI it
becomes an endogenous protective signaling mechanism; and preadministration of metformin (an oral diabetes type 2 medicine) has
a cardio-protective role against MI that is mediated via the AMPKeNOS-mediated signaling cascade [209]. Myocardial infarction
causes death of cardiomyocytes due to a lack of blood supply and
may end up as a fibrotic scar in the myocardium. Scientists have
developed an injectable conductive hydrogel encapsulating plasmid
DNA-eNOS adipose derived stem cells (ADSCs) for the treatment
of MI and the results are significant increase of ejection fraction
(EF), shortened QRS interval in the EKG, smaller infarction size,
lessened fibrosis area, a higher density of capillary vasculature, and
a significant improvement of cardiovascular hemodynamics [210].
The heat shock protein, HSPA12B, has been shown to attenuate
cardiac dysfunction and reduces cardiac remodeling following MI
via an eNOS-dependent mechanism [120]. In addition, inhibition of
TGF-β1 (transforming growth factor) signaling due to eNOS gene
transfer can facilitate ventricular remodeling following MI that is
mediated by angiogenesis and a stoppage of apoptosis [211]. The
chemical compound resveratrol (RSV, 3, 5, 4-trihydroxystilbene),
a naturally polyphenolic phytoalexin, has been shown to attenuate
myocardial ischemia/reperfusion injury mediated via up-regulation
of vascular endothelial growth factor B (VEGF-B)/AMPK/eNOS/
NO signaling mechanisms in isolated rat heart preparations [212].
Finally, β3-adrenergic receptors have been identified as modulators
of heart function and there have been proposals that these
receptors can be potential therapeutic targets for the management
of CVD. Indeed, β3-adrenoreceptor stimulation has been shown to
protect against MI-induced tissue death via activation of the eNOS
protein [213]. Overall, there have been numerous studies that
depict the use of different pharmacological manipulations in order
to delineate the role of the eNOS protein following an episode of
MI. The potential for an eNOS-related pharmacological therapy
protocol appears to be a promising subject in the future.

eNOS and Stroke

Cerebrovascular stroke leads to numerous molecular,
neurochemical, and cellular changes such as massive release
of glutamate and activation of inflammatory cytokines, delayed
neuronal cell death and apoptosis, inflammation and peri-infarct
depolarizations within the peri-infarct zone or ischemic penumbra,
however, neuronal death following ischemia is due to the massive
generation of free radicals like NO [1,139]. The production of NO
from the neural tissues within the brain following an event of
stroke is dependent on differential activation of all 3 isoforms of the
NOSs enzymes: nNOS, iNOS and eNOS, however, exactly how many
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molecules of NO are generated from one molecule of each isoform
are still unknown. In addition, it is yet to be determined exactly how
much is the expression of each NOS protein in different parts of the
affected brain following a stroke which in turn, may determine
how many neurons will be either protected or destroyed. Because
the focus of this review is only on the eNOS isoform, the following
paragraphs will discuss the past and recent literature regarding the
role of eNOS in the pathogenesis of stroke.

glutamatergic and GABAergic neurotransmission during integration
of cardiovascular functions during static exercise. Further, blockade
of the nNOS isoform within the medulla modifies expression of the
nNOS protein and modulates cardiovascular responses during
static exercise. However, the molecular roles of these three isoforms
on NO production and/or protein expression/activity remain to be
investigated. Nevertheless, NO-mediated mechanisms are involved
in cardiovascular homeostasis and its adaptation to exercise.

studied using animal models of cerebral ischemia, and it has been
shown that a transient 90-minute left-sided middle cerebral artery
occlusion (MCAO)-induced focal ischemia followed by 24 hours of
reperfusion significantly attenuates eNOS expression within the
left or ipsilateral RVLM when compared to the abundance of eNOS
within the contralateral RVLM [183]. At the same time, expression
of the eNOS protein derived from the ipsilateral CVLM following
a left sided MCAO is significantly augmented when compared to
the contralateral CVLM [183]. It can be suggested that temporary
ischemic stroke can alter ipsilateral eNOS protein abundance
differentially within the VLM, which may result in a decreased rise
in blood pressure in response to static muscle contraction. Similar
results were observed when measuring the abundance of the nNOS
protein, while there were opposite expressions of the iNOS enzyme
within the RVLM and CVLM in stroked rats [139]. Therefore, eNOS
plays a significant role in modulating cardiovascular responses and
in the pathogenesis of stroke within the brainstem. A search on the
literature shows numerous other investigations regarding the role
of the eNOS enzyme following ischemic stroke in animal models
and are discussed in subsequent paragraphs.

[215]. Moreover, several pharmacological protocols using
medications such as HMG-CoA-reductase inhibitors or commonly
referred to as statins, AT2R antagonists, and Ca2+-channel blockers
increase the expression/activity of eNOS, that in turn, can benefit
CVD via attenuating endothelial dysfunction and promoting global
and regional blood flow [216]. There is an enhanced incidence of
stroke in patients who are homozygous for the eNOS polymorphism
on exon 7 (894G > T) [217]. Thus, further investigations using
the genetic approach as a translational model are crucial to fully
characterize the role of eNOS in stroke of even a transient attack
of cerebral ischemia in humans. The cerebral vascular tree is
geared to rapidly respond to any alterations in systemic blood
pressure in order to maintain cerebral blood flow homeostasis.
The cerebral arteries and arterioles vasoconstrict when there are
elevations of blood pressure and dilate in response to hypotension.
As mentioned previously, endothelial cells-derived NO is known
to regulate the basal vascular tone. Stroke or cerebral ischemia
happens when there is a loss of blood flow and hence a major
goal in the management of ischemic stroke is to rapidly restore
the blood circulation that can reduce further neuronal death. The
infusion of L-arginine or other NO donors following an acute event
of ischemia reduces infarct size by improving blood circulation
within the penumbra region surrounding the infarct [215]. In
addition to NO donors, AT2R blockers and statins or regular
physical exercise also provide neuroprotective effects via eNOS/
NO/cGMP-dependent path-ways as shown by studies using acute
and chronic experimental stroke animal models [218]. Regular
exercise and increase in physical activity also improve endothelial
function which enhances vasodilation and vasomotor function
[219]. Identifying the mechanisms underlying the cardiovascular
benefits of exercise in stroke patients is crucial for improving

While the transdermal glyceryl trinitrate is used in acute stroke,
there is no evidence to recommend the use of the eNOS protein
or drugs that only modifies eNOS in stroke patients. Thus, most
of the investigations for the role of eNOS in stroke are performed
using experimental animals. Several animal studies show that during the early stages of an ischemic brain injury, a surge in eNOSderived NO release protects the neurons from death or apoptosis
mediated via vasodilatation and inhibition of microvascular
aggregation [214]. Thus, the role of eNOS has been extensively

Overall, NO within the brainstem plays a significant physiological
role in modulating cardiovascular responses during static muscle
contraction. Inhibition of nNOS, eNOS, or iNOS within the RVLM
differentially alters glutamate and GABA neurotransmission that in
turn, results in modulation of cardiovascular responses during static
exercise. In contrast, blockade of different NOS isoform activities
within the CVLM causes dif-ferent alterations in cardiovascular
responses to muscle contraction, mediated via changes in glutamate
and GABA levels within the CVLM. Thus, the NOS enzyme within
the medulla appears to provide an interactive mechanistic role in

The eNOS has been a key item in molecular stroke research
for the last two decades because not only it can ameliorate acute
cerebral ischemic injury but also can promote early recovery
following cerebral ischemia via regulating cerebral blood flow,
promoting homeostasis, reducing inflammation, and generating
angiogenesis as well as neurogenesis. Endothelial NOS expression
increases very early after a cerebral ischemic insult. In animal
models of stroke, intravenous administration of the eNOS substrate,
L-arginine, during ischemia has been shown to be neuroprotective
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treatment strategies for stroke. It is important to understand the
mechanisms within the brainstem that integrate the function of
the nervous and CVS during static exercise and following cerebral
ischemia. Also, it is critical to uncover the mechanisms by which
exercise training in stroke patients can improve the compromised
relationship between the nervous system and the CVS.

Stroke-prone spontaneously hypertensive rats exhibit an
attenuated expression of the eNOS protein within the cerebral cortex
and within the endothelium [220]. Furthermore, AT2R blockade
potentiates cerebral circulation and can lessen further neuronal
death [221]. Statin medications have fibrinolytic and antithrombotic
effects and attenuate aggregation of platelets mediated via an
elevated eNOS-expression-derived NO formation in MCAO rats222.
Another mechanism by which an increased expression/activity of
eNOS is beneficial in stroke patients is by promoting an increased
cerebral circulation through the process of angiogenesis from
precursor stem cells that are increased in ischemic brain injury,
and that NO works as a messenger/neuromodulator that promotes
endothelial cell proliferation and migration. This angiogenesis is
also regulated by several growth factors such as TGF-β2, Plateletderived growth factor (PDGF), Vascular endothelial growth factor
(VEGF), and Basic fibroblast growth factor 2 (BFGF-2), which are
highly expressed following a cerebral ischemic insult and that eNOS
can stimulate angiogenesis by releasing low concentrations of NO
[223]. Overall, eNOS preserves collateral blood flow following an
ischemic brain injury and thereby prevents further neuronal
damage making it a key protein for future use in stroke research
because eNOS has the ability to not only ameliorate acute ischemic
insult but also promote early recovery. The efficacy of NO is studied
in humans with the idea of managing hypertension in acute stroke
and the result is that transdermal glyceryl trinitrate lowers blood
pressure but does not improve the functional outcome (The
RNOS Trial Investigators, 2016). Finally, the drug Rapamycin®,
(also known by its generic name, Sirolimus) is a natural product
isolated from Streptomyces hygroscopicus that is found on the
island of Rapa Nui inhabitants (Polynesian inhabitants) of Easter
Island in the Pacific Ocean near Chile [224]. This Rapamycin® is a
clinically approved mammalian target of rapamycin inhibitor that
has been shown to possess neuroprotection in animal models of
ischemic stroke. However, the mechanism of Rapamycin®-induced
neuroprotection is still unknown although sirolimus-eluting
stents are safe and effective in preventing restenosis in de novo
coronary artery lesions. A recent study has shown that Rapamycin®
significantly increases collateral perfusion and reperfusion of the
cerebral blood vessels in both Wistar and comorbid spontaneously
hypertensive rats that appear to be mediated via augmenting
the activation of eNOS [225]. This suggests that Rapamycin® can

be used in the treatment protocol in patients with stroke as this
drug increases collateral blood flow and also in patients who
have undergone thrombolysis or thrombectomy by improving
cerebral blood flow circulation [225]. Manipulations of the eNOS
protein with its agonists/antagonists administered either locally or
systemically and their effects on cardiovascular function following
stroke should be further explored in order to ascertain possible
therapeutic benefits/disadvantages that in turn, may lead to the
development of drugs for the prevention or treatment of stroke. In
summary, eNOS has an important in the pathogenesis, prevention,
and management in a situation of ischemic brain injury or stroke.

Highlights and Conclusion

The intricate and critical relationships between the eNOS
protein and the CVS in both physiological and in the pathogenesis
of a diverse array of CVD have been discussed. The eNOS isoform
induces autocrine and paracrine signaling factors that modulate
blood flow, circulation, and neural activity via the production of
NO. The resulting vasodilation elicited from the catalytic creation
of NO allows the maintenance of tonicity and blood flow within
the circulation. The detrimental impacts of eNOS uncoupling are
involved in the pathogenesis of numerous CVD.
In conclusion, most of the plethora of the roles of eNOS in both
physiological and pathological states of the CVS that are related to
the eNOS gene and chromosome 7, eNOS uncoupling, differential
regulations via receptors- and drug-mediated pathways,
cardiovascular autonomic reflexes, baroreflex, and the Exercise
Pressor Reflex have been elaborated. Moreover, the interrelated
relationship between eNOS, the CVS, the CNS, and the pathogenesis
of several CVD such as hypertension, atherosclerosis, MI, and stroke
that may happen because of disrupted or reduced eNOS activity
are critically evaluated. Further research on the development of
drugs that can modulate or affect eNOS expression/activity, eNOS
uncoupling, and related regulatory mechanisms can contribute to
the better understanding of the relationship between eNOS protein
and the CVS/CVD. Finally, the pathogenesis of several CVD related
to eNOS should be extensively clarified not only to prevent diseases
like hypertension and stroke but also be used as a foundation of
their treatment and follow-up.
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